Prestige Consumer Healthcare, listed on the New York Stock Exchange under the ticker PBH, has upgraded its financial outlook for fiscal year 2027, signaling stronger-than-expected growth in both profitability and top-line revenue. The company raised its adjusted earnings per share (EPS) guidance from a previous range of $4.42-$4.51 to a new band of $4.55-$4.65. This upward revision places the midpoint of the new guidance above the analyst estimate of $4.53, indicating improved operational confidence and margin resilience.

Simultaneously, Prestige Consumer Healthcare increased its full-year sales guidance significantly. The revised sales outlook now stands at $1.290 billion-$1.315 billion, a substantial increase from the earlier projection of $1.100 billion-$1.121 billion. This revised range also exceeds the consensus analyst estimate of $1.179 billion, suggesting that the company anticipates robust demand or successful execution of its commercial strategies in the coming quarters.

Revised Financial Guidance

The updated figures reflect a notable shift in the company’s trajectory for FY2027. By raising both the EPS and sales bands, management is communicating that underlying business performance is tracking ahead of initial expectations. The gap between the new lower-bound sales figure of $1.290 billion and the previous upper bound of $1.121 billion highlights a significant expansion in revenue potential.

What the Numbers Show

The divergence between the revised sales guidance and the analyst estimate is particularly material. While the EPS revision is modestly above the street estimate, the sales uplift is more pronounced, adding approximately $111 million to $136 million to the expected annual revenue compared to the prior ceiling. This suggests that the earnings improvement may be driven not just by cost efficiencies but by genuine volume or price realization gains. The ability to raise the floor of the sales guidance well above the previous ceiling indicates a strong momentum shift in the company’s core markets.

Prestige Consumer Healthcare Inc. has priced a private offering of $400 million in aggregate principal amount of 6.25% senior notes due 2034. The notes are senior unsecured obligations of its wholly-owned subsidiary, Prestige Brands, Inc., and are guaranteed by the company and certain domestic subsidiaries. The company intends to use the net proceeds from the offering, combined with cash on hand, to redeem all $400 million of Prestige’s outstanding 5.125% Senior Notes due January 2028 and to pay related fees and expenses. The sale of the notes is expected to be completed on or about July 15, 2026, subject to customary closing conditions.

The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended, or to non-U.S. persons in compliance with Regulation S. The notes have not been registered under the Securities Act or any other jurisdiction's securities laws and may not be offered or sold in the United States without registration or an applicable exemption.

Key Details of the Offering

Prestige Consumer Healthcare markets, sells, manufactures, and distributes consumer healthcare products to retail outlets in the U.S., Canada, Australia, and other international markets. The company’s portfolio includes brands such as Breathe Right, Monistat, Summer’s Eve, BC, Goody’s, Clear Eyes, TheraTears, DenTek, Dramamine, Fleet, Chloraseptic, Luden’s, Compound W, Little Remedies, Boudreaux’s Butt Paste, Nix, Debrox, Gaviscon, Hydralyte, and Fess.